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Abstract 
In a low inflammatory skin environment, Langerhans cells (LCs) – but not dermal dendritic 
cells (dDCs) – contribute to the pivotal process of tolerance induction. Thus LCs are a target 
for specific-tolerance therapies. LCs reside just below the stratum corneum, within the skin’s 
viable epidermis. One way to precisely deliver immunotherapies to LCs while remaining 
minimally invasive is with a skin delivery device such as a microprojection arrays (MPA). 
Today’s MPAs currently achieve rapid delivery (e.g. within minutes of application), but are 
focussed primarily at delivery of therapeutics to the dermis, deeper within the skin. Indeed, 
no MPA currently delivers specifically to the epidermal LCs of mouse skin. Without any 
convenient, pre-clinical device available, advancement of LC-targeted therapies has been 
limited. In this study, we designed and tested a novel MPA that delivers ovalbumin to the 
mouse epidermis (eMPA) while maintaining a low, local inflammatory response (as defined 
by low erythema after 24 hours). In comparison to available dermal-targeted MPAs (dMPA), 
only eMPAs with larger projection tip surface areas achieved shallow epidermal penetration 
at a low application energy. The eMPA characterised here induced significantly less 
erythema after 24 hours (p = 0.0004), less epidermal swelling after 72 hours (p < 0.0001) and 
52% less epidermal cell death than the dMPA. Despite these differences in skin 
inflammation, the eMPA and dMPA promoted similar levels of LC migration out of the skin.  
However, only the eMPA promoted LCs to migrate with a low MHC II expression and in the 
absence of dDC migration. Implementing this more mouse-appropriate and low-inflammatory 
eMPA device to deliver potential immunotherapeutics could improve the practicality and 
cell-specific targeting of such therapeutics in the pre-clinical stage. Leading to more 
opportunities for LC-targeted therapeutics such as for allergy immunotherapy and asthma. 
 
Keywords: Langerhans cell targeting; Epidermis; Microprojection; Microneedle; Skin 
delivery; Skin inflammation 
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Introduction 
Many therapies aimed at immune downregulation – such as allergy immunotherapy (AIT) 
[1], asthma [2], chronic obstructive pulmonary disease [3] and type I diabetes [4] – require 
tolerance-specific priming via antigen-presenting cells (APCs). One example of an APC able 
to serve this function is the Langerhans cell (LC) which resides in the skin’s viable epidermis. 
LCs play an important role in both immune defence and immune tolerance for skin 
infections, inflammations and tumours [5]. During homeostasis, LCs are pre-committed to 
support the maintenance of tolerance, unlike antigen-primed dermal dendritic cells (dDC) that 
often induce immunogenicity [6]. Therefore, therapy to boost immune tolerance ideally 
requires specific delivery of antigens to the LCs within the viable epidermis.  
 
LCs are competent in presenting antigens through both MHC I and MHC II to CD8+ and 
CD4+ T cells, respectively [5]. They can also induce either specific effector T helper type 2 
cell (Th2) [7] or specific regulatory T cell (Treg) responses [8-10]. This ability to induce 
contradictory T cell responses to the same antigen depends on the local inflammatory 
environment or adjuvant that the LC is exposed to. That is, high levels of inflammation in the 
viable epidermis (e.g. removing the stratum corneum via tape-stripping) increases the 
expression of MHC II on LCs that migrate to the draining lymph nodes and bias signalling 
towards either Th1 or Th2 differentiation [11-14]. Conversely, lower levels of inflammation 
in the viable epidermis (e.g. topical application of antigen, [13]), favours regulatory pathways 
including Tregs, and the secretion of interleuken-10 and tumour growth factor-beta [12, 15]. 
Continuously sampling LCs in the low inflammatory homeostasis state can present antigens 
to both resident memory Tregs in the skin and circulate to Tregs within the skin draining 
lymph node [9].  Below the viable epidermis, the dermis contains a large support network for 
priming of the Th1 and Th2 pathways and thus is better suited for Th1 and Th2 activation-
based therapies [7, 16].  Targeting the viable epidermis creates a unique opportunity to 
enhance specific-Treg responses without activating inflammatory cells within the dermis 
below.  
 
Targeting and activating LCs in the thin epidermis using the common mouse model is 
notoriously difficult for several reasons.  First, the target site is much thinner than its human 
counterpart (mouse and human viable epidermal thicknesses, are respectively ~ 20 µm and 
~50-100 µm) [17].  Second, small therapeutics do not specifically target the viable epidermis 
and instead often enter systemic circulation, increasing the chance of an inflammatory 
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response to the antigen [18, 19]. Third, most of the therapeutics used for AIT are too large to 
diffuse readily into the skin (i.e. > 500 daltons). Therapies below this size delivered by 
traditional topical patches can take hours to days of application to deliver the required dose 
[19, 20].  
 
The unmet challenge is for a range of molecules to effectively bypass the stratum corneum, 
while targeting the viable epidermis, with low-inflammation. To do this, the stratum corneum 
must be either removed, penetrated or hydrated. For example, combining topical patches with 
devices that removes the stratum corneum, such as tape-stripping certainly increases delivery 
efficiency [21] and LC activation [11]. However, removing the stratum corneum, induces 
local skin inflammation including  prolonged skin erythema (over 24 hours) and activating 
Th2-mediated differentiation [11, 22], rather than tolerance. A review by Larraneta et al. [23] 
on transdermal devices highlights the importance of reducing local erythema, particularly for 
repetitive treatments (such as AIT) to maintain patient compliance. Overall, topical patches 
require an excess of therapeutic drug and long application times making them costly and 
difficult for patients to comply with but cannot feasibly delivery large sized therapeutics such 
as AIT quickly without mediating inflammation. Clearly, a more practical delivery device is 
required for quicker, low inflammatory viable epidermis targeting. 
 
Current research and development efforts are directed at producing transcutaneous devices to 
deposit therapies either with quick epidermal delivery or alongside a low skin inflammation 
in mice but not with both characteristics. Quick delivery is defined here as application within 
15 minutes and is vitally important for both consistent dosing through the skin and patient 
compliance [24-26]. Such rapid delivery methods include biolistic microparticle delivery  
[27], ultrasound-enhanced delivery [28] and ablative micro-fractional laser [29]. While 
biolistic microparticle delivery and ablative micro-fractional laser can target the viable 
epidermis within minutes, they are also highly inflammatory (e.g. [30]) relative to the lower-
inflammatory hydration chamber device called Viaskin® [31]. Viaskin® relies on actively 
enhancing diffusion through the stratum corneum but remains slow to delivery. Indeed, no 
mouse-based viable epidermis device is available to both deliver quickly whilst inducing only 
a low level of skin inflammation. A class of device with the potential to meet this need is the 
microprojection array (MPA), which make up part of the microneedle field.  
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MPAs are defined here as patches with an array of solid or dissolvable projections no taller 1 
mm high each. The primary interest for MPA research and development in the last two 
decades has been on vaccination. MPAs are a more practical device than other skin delivery 
devices and is more tolerated by medical staff and patients alike [32]. Additionally, their 
micro wound delivery mechanism elicits activation of the immune response, mitigating the 
need for additional chemical adjuvants [33]. Most MPAs tested on human skin have 
penetrated into the epidermis and dermis, though some may indicate epidermal-only 
penetration is achievable with current conical-projection designs since the human epidermis 
is much thicker than mice, though no specific penetration measurements were reported [34]. 
However, there have been no pre-clinical mouse immune tests with MPAs that successfully  
penetrate only into the epidermis, causing a gap the translation of delivering therapeutics to 
the epidermis between mice and human trials. Dermal-targeted MPAs (dMPAs) have a broad 
design range to induce a variety of skin inflammation responses. For example, a dMPA of 
with five projections each 750 µm (H) applied to mouse skin by hand resulted in erythema 
that cleared within 24 hours [35]. Using a higher density of projections such as dMPAs of 
21,000 projections/cm2, ranging in length of 40-190 µm applied to mouse skin by a spring 
loaded applicator resulted in persistent erythema up to 48 hours [36]. Applicators can 
maintain a consistent MPA application into the skin, but can impart additional energy into the 
skin and increase the inflammatory skin response. Indeed, dMPAs have been designed and 
used in many shapes, densities and materials and have been extensively reviewed elsewhere 
[37]. An MPA to specifically target the mouse epidermis, with low inflammation, however, is 
yet to be reported. 
 
Here, we hypothesised that an epidermal-targeted MPA (eMPA) with low, local 
inflammatory characteristics would specifically target coated therapeutics to LCs without 
enhancing an inflammatory response. To test this hypothesis, we first designed and tested the 
delivery parameters of an eMPA for mice. We then characterised the local skin inflammatory 
response of the application area of the eMPAs. Thirdly, we assessed the effect of eMPA 
application on LC migration. We found that in order to combine epidermal delivery with a 
low inflammatory application energy, the eMPA projection design required a higher tip 
surface area (relative to a dMPA). This eMPA elicited low epidermal inflammation and, 
concurrently, increased LC activation with low MHC II expression without inducing dermal 
dendritic cell (dDC) migration. These findings of LC-activating, low-inflammatory mouse 
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eMPAs could have wide-reaching implications, providing a more practical delivery platform 
to deliver tolerant based therapeutics in a pre-clinical model.  
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Methods 
Animals 
Female 6-8 week old BALB/c mice were obtained from the Australian Research Council 
(Perth, W.A.). Animals were maintained in accordance with The University of Queensland 
Animal Ethics guidelines. All experimental procedures were approved under ethics AIBN 
556/12, AIBN 042/16 and AIBN 043/16. When applying MPAs, animals were anaesthetised 
by intraperitoneal injection with a Ketamine (50 mg/kg) and Xylazil (10mg/kg) mix (both 
Troy laboratories, Smithfield, Australia) and its action reversed with atipamezole (Antisedan; 
Pfizer, Australia) diluted 1:10 in Phosphate Buffered Solution (PBS). Twenty-four hours 
prior to MPA application, dorsal and flank hair was removed using electric hair clippers 
(Wahl, Stirling IL, USA), then chemically removed with a depilatory cream (Nair, Church & 
Dwight, Trenton NJ, USA). After 24 hours, histological analysis of the Nair skin compared to 
naïve skin found that Nair did not affect the skins thickness or cellular infiltration as 
previously reported [38]. All injections were performed using a 31G needle. 
 
Microprojection array fabrication 
Silicon MPA fabrication 
Silicon MPAs were fabricated as previously described [39] with assistance from the 
Australian National Fabrication Facility Queensland Node. The area of the silicon wafer 
within 90% consistency was isolated and used for moulding (‘silicon master’). Projection 
designs included conical-shaped, 207 µm ± 5 µm tall projections at 10,000 (10k) 
projections/cm2 (p/cm2), herein referred to as conical-MPA (Figure 1A) or slit shaped, 110 
µm ± 3 µm tall projections at 7k p/cm2 (Figure 1B), herein referred to as slit-MPA. A similar 
conical-MPA design was first reported in Depelsenaire et al. [33] (previously named 
‘Nanopatch’) and slit-MPA design in Crichton et al. [40] (previously named ‘Transdermal 
patch’). Silicon MPAs were imaged using secondary scanning electron microscopic (SEM) 
imaging (Hitachi, SU3500).  
 
Polycarbonate hot embossing of MPAs 
To fabricate polycarbonate MPAs, a polydimethylsiloxane (PDMS) mould was made by 
pouring a 1:12 Sylgard-184 mixture over a salinized silicon master (using 
trichloro(octadecyl)silane, Sigma Aldrich 104817). Polycarbonate projections were hot 
embossed at 3,500 N as per Yeow et al. [39] with the following stacking: bottom platen, 1 
mm polycarbonate foil, PDMS mould, top platen, 1 mm-thick graphite pad. Repeated use of 
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PDMS mould (over 5 repeats) required 3,600 – 4,000 N pressure to continue producing 
consistent projections. Conical-MPA projections became 190 ± 4.7 µm tall (Figure 1C) and 
slit-MPA projections became 95 ± 2.4 µm tall (Figure 1D). Finally, polycarbonate MPAs 
were diced to 4 x 4 mm squares using a 0.1 mm nickel blade EVG dicer and treated with 
oxygen plasma prior to formulation coating to increase wettability. MPAs with a surface area 
of 16 mm2 had 1,600 projections per Conical-MPA and 1120 projections per slit-MPA. 
Polycarbonate MPAs were splutter coated with iridium then imaged using back-scatter 
scanning electron microscopic (BS-SEM) imaging (Hitachi, SU3500). Surface area of 
projections within the epidermis was calculated by measuring 10-20 projections from SEM 
images. The height (H) used was the average depth of the epidermis calculated in this report 
(26 µm). The following equations were used to calculate the average surface area of one 
projection then multiplied by the number of projections per MPA. 
 Lateral surface area of a cylinder for conical: 𝐴 = 2𝜋𝑟26 × 1600 projections (µm2) 
 Surface area for slit (i.e. 2 × trapezoid + 2 × equilateral triangle surface areas): 
  (2 ((
27+𝑊
2
)𝐻))+ (2(
𝐻∗𝐷
2
)) × 1120 projections (µm2) 
 
Therapeutic coating of microprojection arrays 
Polycarbonate MPAs were coated as previously described [41]with a final concentration of 
100 mM PBS and 1% methylcellulose (HG 60). Either ovalbumin (OVA, Sigma, Grade V, 
98%, filtered through 0.22 µm) diluted in PBS or PBS alone (placebo) was added to the 
coating solution. A 14C-OVA-based coating assay was used  to calculate delivered dose [42]. 
The mean delivery efficiency of each condition (see SUPP 1) was measured and the OVA 
concentration was adjusted in each formulation to ensure each OVA-coated MPA delivered 
0.1 µg of OVA while the concentration of the excipients stayed the same for each (e.g. an 
MPA condition with a delivery efficiency of 10% would be coated with 1 µg OVA). To coat 
the formulations, MPAs were fixed in place on a coating rig with a vacuum before 
formulation was dispensed. The rotating MPA was dried with a jet stream of nitrogen gas at 
23 °C. Consistent coating was confirmed with BS-SEM (Hitachi, SU3500) (SUPP 2). 
 
Application of microprojection arrays to skin 
To prepare the skin for application, a fold of flank skin was extended and fixed as described 
in Coffey et al. [43]. The skin was not over stretched and was applied to in its natural tension 
(Figure 1E insert). A push-through spring loaded applicator was used to accelerate the MPA 
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over 1 - 2 mm of space before contacting the skin fold as previously described [44]. The 
MPA was removed after 2 minutes, after which the desired dose of formulation was 
deposited in the skin, as confirmed previously [41]. A maximum of eight applications could 
be applied per mouse without applications overlapping (Figure 1E). The 36 gram plunger of 
the push-through applicator was loaded to deliver MPAs with application velocities (and 
energies) of 0.9 m/s (15 mJ), 1.3 m/s (30 mJ), 1.8 m/s (60 mJ), 2.3 m/s (100 mJ) or 3.1 m/s 
(170 mJ). 
 
Figure 1: Representative images of MPA design and application using a mouse model. 
Secondary SEM image of silicon masters of (A) conical-MPA projections and (B) slit-MPA 
projections. BS-SEM image of polycarbonate moulded MPAs coated in iridium of (C) 
conical-MPA and (D) slit-MPA. Scale bar for A-D is 100 µm. (E) Photograph of flank 
positioning during MPA application on a mouse, insert depicts close up of 4 x 4 mm MPA 
applied to flank skin fold with push-through applicator plunger visible. 
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Measurement of penetration depth and epidermal displacement 
Fluorescent penetration tracks were measured using histology to quantify skin penetration 
depth. Polycarbonate MPAs were coated with an OVA-based formulation including 0.05% 
yellow-green 200 nm FluoSpheres (F8811, Thermo Fischer scientific, USA), applied to 
mouse skin for 2 minutes and penetration depth analysed as previously published [45]. A 
minimum of three 20 µm thick cyro-sections from n = 3 mice were imaged at 20x and 
analysed using the Zeiss confocal microscope LSM510 with Zen software 2010. Only MPA 
conditions that resulted in visual fluorescent penetration were imaged for quantification. 
 
Assessment of epidermal inflammation 
To assess skin erythema, OVA-coated eMPA and dMPAs were applied to mouse flanks and 
then imaged at t = 0, t = 24 and t = 72 h after application. Images were scored using the 
Draize Index as per [46, 47]. Representative images for each condition can be found in SUPP 
3. Viable epidermal-specific swelling was quantified after eMPA, dMPA or a 20 µl i.d (31 G) 
injection. Applied skin was excised (~2 mm deep) at t = 24 or t = 72 h, fixed (10% Neutral 
Buffered Formalin for 2 h), embedded in paraffin and sectioned to 10 µm thick. Sections 
were stained with heamatoxylin (HHS32, Sigma-Aldrich) and eosin (E4009, Sigma-Aldrich) 
(H&E) and mounted under dibutylphthalate polystyrene xylene, DPX (3197, Ajax, Thermo 
Fischer, USA). Stained sections were imaged with an Aperio slide scanner microscope and 
epidermal and dermal thicknesses were measured at 20x using ImageScope software. The 
thickness of each application condition was compared to naïve skin of three mice. Note here 
that skin thickness in paraffin embedded sections were consistently thinner than cyro-sections 
and so comparisons were made to naïve skin within respective mediums. 
 
Discrimination of viable / non-viable cells via microscopy 
To discriminate between live and dead cells, the viability dyes Acridine Orange and Ethidium 
Bromide were used as described elsewhere (e.g. [30, 33]), with the following adaptions for 
thicker flank skin compared to previously used ear skin. Briefly, OVA-coated and applied 
eMPAs and dMPAs or intradermal injection (i.d.) applied flank areas were excised 
immediately after euthanasia with at least 3 mm excess border around the site. Skin was 
submerged under a mix of Acridine Orange (15 µg/ml) and Ethidium Bromide (50 µg/ml) in 
PBS and incubated at 37 °C for 1.5 hr. MPA-applied skin was imaged (20x, 40-70 µm deep 
at 1 µm z-stack intervals) using the Zeiss LSM510 confocal microscope. Ethidium Bromide 
positive dead cells were quantified using Imaris software (assuming a 5.18 µm cell diameter). 
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The number of dead cells in an MPA contact area of 16 mm2 were extrapolated from 3-4 3D-
images (1.095-1.460 mm2) of each application repeat.  
 
Flow cytometry 
Flow cytometry was used to identify skin APCs migrating to the inguinal draining lymph 
node (dLN) after eMPA or dMPA application compared to naïve dLNs. Total numbers of 
DCs, and LC and dDC subsets were quantified per flow sample of each dLN at either t = 24, 
48 or 72 h after a PBS MPA (left dLN) and a 0.1 µg OVA MPA (right dLN) application. 
dLNs were processed individually, however, based on Kool et al. [48], an ipsilateral cross 
over of cell migration from skin application can make up to 20% of the opposite dLNs cell 
content. dLN were digested with collagenase D (1 mg/mL) and DNase I (0.2 mg/mL) for 30 
minutes at 37oC. dLNS were individually homogenised, washed through a 0.22 µm strainer 
and resuspended in sterile 0.1% foetal calf serum (in PBS) dilution buffer. Aqua (cat:L34966, 
Thermo Fisher) was used for live/dead differentiation and anti-mouse monoclonal antibody to 
CD16/32 (2.4G2, cat:553142, BD Pharmingen) blocked exposed Fc sites. Then anti-mouse 
monocolonal antibodies against CD11c (N418, cat:25-0114-82, eBioscience), CD11b 
(M1/70, cat:101226, BioLegend), CD326 (EpCAM) (G8.8, cat:118214, BioLegend), MHC II 
(M5/114.15.2, cat11-5321.85, eBioscience) were added, and associated isotypes were used 
for controls (spleen). Cells were incubated, washed and analysed as previously published 
[49]. Cells were acquired using the Gallios cytometer and analysed with Kaluza software. 
 
Statistics 
Statistics were performed in Graphpad Prism (version 6 or 7 for Windows; GraphPad 140 
Software, La Jolla, CA) using unpaired t-tests assuming Gaussian distribution between either 
naïve or sensitised and treated groups. Statistical differences between a number of 
comparable groups was assessed using a one-way ANOVA (Supplementary figures only). P-
values of ≤ 0.05 were considered as significant. All values are expressed as mean ± standard 
deviation (SD) unless otherwise stated. All groups that resulted in a significant (p ≤ 0.05) 
difference with another group within the graph was denoted with an asterisks equal to the 
significance grouping: *p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. All non-
significant results (p > 0.05) have no symbol in graphs. 
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Results 
Slit-shaped polycarbonate MPAs primarily deliver coating to the epidermis 
To establish MPAs for epidermal targeting, we first manufactured MPAs in polycarbonate 
material. As reported previously by Yeow et al. [39], polycarbonate is a well-suited material 
for MPA fabrication including relatively low cost, high modulus and high impact strength. 
The hot embossing procedure of the same silicon master also allows for easy replication of 
consistent MPA projections unlike the dry etching process of silicon MPA fabrication.  Here, 
hot embossing of high-density projections required optimisation of the PDMS mould to 
increase flexibility. Here, we found a ratio of 1:12 curing agent to PDMS was better suited 
(i.e. fewer breakages) for repeated, high-pressure hot embossing (SUPP 4), which differed 
from the recommended 1:10 ratio. By optimising the PDMS mould and hot embossing 
procedure, we were able to reproduce silicon master MPAs into polycarbonate MPAs using 
the same mould multiple times. The polycarbonate projections retained the same base width 
but were 10-15% (20 µm) shorter than their silicon masters (compare Figure 1A to C and B 
to D). Polycarbonate slit-MPA tips increased in width (see Figure 2A) from an average of 
0.71 ± 0.15 µm to 2.16 ± 0.35 µm (Figure 2B) similar to Yeow et al. [39]. Figure 2C 
indicates that conical-MPA or slit-MPAs that penetrate 15 µm equate to the surface area of 
the bevel of a 27 – 31G needle used for intradermal injections into mouse skin. The 
polycarbonate projections were significantly blunter than the master but maintained > 85% 
projection length and 100% projection width and depth of the master projections. 
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Figure 2: Surface area of polycarbonate projections. (A) BS-SEM image of slit-MPA tip 
from (i) silicon or (ii) iridium-coated polycarbonate MPA, scale bar is 10 µm. (B) Plot of tip 
width quantification for silicon, ‘Si’, and polycarbonate, ‘PC’, slit-MPA projections. (C) 
Calculated total projection surface area of a polycarbonate MPA (y-axis) that would be 
present in the skin depending on the depth of penetration (x-axis) including background 
shading of average depth of stratum corneum, ‘StC’, viable epidermis, ‘VE’, and dermis, ‘D’. 
Plot includes surface area of intradermal (i.d.) affected area using a 27, 29 and 31G needle 
assuming only bevel of needle is inserted.  
 
To target the epidermis specifically, polycarbonate conical- and slit-MPAs were applied at a 
range of application energies (15, 30, 60 or 100 mJ) and BS-SEM confirmed consistent 
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removal of coating (Figure 3A). As BS-SEM is not a reliable method to assess penetration 
depth due to skins viscoelasticity during application, penetration was assessed by histological 
analysis of applied skin sections using fluorescently coated MPAs (Figure 3B). As the mouse 
epidermis (StC + viable epidermis) in the flank averages 26.5 ± 4.6 µm thick (Figure 3C), we 
initially tested shorter (75 µm), conical-MPAs. The combination of short and blunt 
projections did not penetrate the skin at a low application energy (data not shown), unlike 
similar short (40 µm) but sharp conical-MPAs reported to penetrate mouse flank skin [36]. 
On the contrary, Figure 3D shows penetration of 190 µm long conical-MPAs deposited 
coating beyond the epidermis at the lowest application energy (15 mJ, 31.5 ± 9.0 µm). 
However, the slit-MPA consistently delivered coating into the viable epidermis (15.7 ± 9.2 
µm) using a 30 mJ application energy. Based on these observations, we defined the slit-MPA 
applied at 30 mJ as the ‘eMPA’ and the conical-MPA applied at 100 mJ as the ‘dMPA’ for 
comparison (which delivered to a depth of 75.2 ± 26.3 µm, Figure 3D). Figure 3E represents 
the total projection surface area / volume within the skin strata based on the average depth of 
penetration for both eMPA and dMPA given in Figure 3D. Once applied, the total surface 
area of the eMPA and dMPA projections is 1.09 ± 0.64 mm2 and 5.22 mm2 within the viable 
epidermis respectively (Figure 3F, left). This equates to a displacement volume of 0.002 ± 
0.001 mm3 (0.47%) or 0.055 mm3 (13.32%) within the 0.416 mm3 (i.e. 4 x 4 x 0.025 mm) 
volume of the viable epidermis respectively (Figure 3F, right). Although an intradermal 
injection bevel insertion affected a smaller surface area in the epidermis (0.869 mm2, based 
on a 10 degree insertion) than the MPAs, it displaced an order of magnitude more volume 
(0.032 mm2) than the eMPA and an order of magnitude less than the dMPA. Plotting the 
epidermal surface area multiplied by the application energy (mm2 × mJ) highlights the log10 
correlation between the three devices (SUPP 5). Note here that the energy of the i.d. injection 
was approximated to 0.83 mJ based on previously published insertion energies [50]. 
Additionally, the total tip surface area of the eMPA (0.062 ± 0.01 mm2) was 1.5-fold higher 
than dMPA (0.041 ± 0.01 mm2) (Figure 3G). By normalising the energy of application to the 
total tip surface area, the eMPA was applied at 5x less energy per mm2 than the dMPA (483 
and 2439 mJ / mm2, respectively).  Taken together, these results provide evidence that slit-
MPAs, with significantly higher tip surface areas than conical-MPAs, are better suited for 
epidermal only delivery using low application energies. By contrast, even when using the 
lowest application energy tested, higher density conical-MPAs deliver beyond the viable 
epidermis into the dermis and therefore were deemed not suitable for epidermal only 
delivery. 
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Figure 3: Slit-MPAs applied at 30 mJ deposited coating to the epidermis of mouse skin. 
(A) BS- SEM of applied OVA-coated MPA per projection shape and application energy. 
Images indicate areas of coating (dark) and removed coating (light), inset include black arrow 
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of length of coating removed, scale bars: 100 µm, 10 µm inset. (B) Confocal images of 20 
µm sections of green FluoSpheres delivered by MPAs into mouse flank skin, scale bar: 200 
µm. Arrow indicates one of the projection tracks per image (arrow 75 µm long). (C) Depth of 
the epidermis using cryo preserved sections of naïve skin. (D) Skin penetration depth 
measurements of MPA projections from n = 3 mice, totalling n = 41-117 measurements, 
mean ± SD. (E) An outline of the average depth of eMPA and dMPA penetration into the 
skin, based on Figure 2D, shading indicates the area of the projection within epidermis. (C-E) 
The average skin strata thicknesses: orange (‘StC’ stratum coreum), green (‘VE’ viable 
epidermis) and pink (‘D’, dermis), where StC + viable epidermis together make up the 
epidermis, ‘E’. (F) Calculated epidermal surface area (left) and volume displaced (right) of an 
applied 31G needle bevel (i.d.), eMPA or dMPA. eMPA includes error based on penetration 
depth while dMPA epidermal area and volume does not differ within the SD of penetration. 
(G) Total surface area of polycarbonate tips for conical-MPA or slit-MPA, n = 7 and 14 
projection tip measurements respectively. 
 
Application of eMPAs resulted in a lower inflammatory response than dMPAs 
Skin inflammation of the applied area was assessed by erythema, epidermal thickness and 
cell viability quantification. Progression of erythema was captured by photographic images 
taken at 5 minutes (t = 0 h), t = 24 h and t = 72 h after application (SUPP 3). Photo images 
were then scored using Draize score index for erythema (Figure 4A). Immediately after 
application, the application site of MPA or i.d. bleb was clearly visible (SUPP 3). The eMPA 
induced significantly less erythema than the dMPA at t = 0 h (p = 0.0002), t = 24 h (p = 
0.0004) and t = 72 h (p = 0.025) (Figure 4B). All i.d. injections received a Draize score of 
zero. 
 
Next, we assessed the effect of the eMPA application alone (PBS coating) on the swelling of 
the viable epidermis using H&E-stained histology sections (Figure 5A). The thickness of the 
naïve viable epidermis averaged 15.9 ± 5.0 µm and the thickness of the dermis averaged 
178.4 ± 29.6 µm. The dermis became thinner 24 h after each application (dMPA p < 0.0001, 
eMPA p = 0.007, i.d. p < 0.0001, SUPP 6). Twenty-four hours after both the dMPA (p < 
0.0001, 19.8 ± 5.4 µm) and eMPA application (p = 0.002, 18.6 ± 6.1 µm) the viable 
epidermis increased in thickness (Figure 5B). Concurrently, the thickness of the viable 
epidermis after i.d. injection reduced slightly at 24 h (p = 0.038, 13.4 ± 7.9 µm) but had 
returned to naïve thickness by 72 h (15.4 ± 6.2 µm).  By 72 h, the eMPA viable epidermis 
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thickening had dissipated (14.1 ± 6.2 µm) while the dMPA maintained an inflamed viable 
epidermis (20.36 ± 6.8 µm). These results show that the eMPA induces significantly less 
local inflammation in the viable epidermis than the dermal-targeted device. 
 
 
Figure 4: eMPA resulted in lower erythema than dMPA at t = 0, 24 and 72 h. (A) 
Representative images of MPA-applied flank skin that scored (left to right), 1, 2 and 3 using 
Draize scoring, scale bar: 1 mm. (B) Plot of Draize score of application sites t = 0, 24 and 72 
h after dMPA or eMPA application, n = 3 – 9 mice and n = 6 – 18 applications. 
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Figure 5: eMPA evoked less swelling of the viable epidermis than dMPA. Swelling of the 
epidermis and dermis 24 h and 72 h post application of placebo formulation/injection. (A) 
Representative image of H&E-stained flank skin sections (10 µm) of  naïve, 24 h post-
dMPA, 72 h post-dMPA, 24 h post-eMPA, 72 h post-eMPA, 24 h post-20 µl i.d. and 72 h 
post-20 µl i.d, scale bar: 200 µm. (B) Epidermal skin thickness measured from H&E-stained 
sections of n = 3 mice and n = 54-179 measurements per condition, dotted line indicates 
mean of naive measurements (n = 3 mice with n = 4 sections each).  
 
The physical application of devices to the skin, such as tattoo needles [51] and the 
Nanopatch™ (a high-density dMPA applied to the skin to deliver vaccine [33]) are known to 
induce localised cell death. As cell death is associated with an increased pro-inflammatory 
response [52-54], we sought to quantify the effect of the MPAs used here by quantifying non-
viable cells in 16 mm2 of the epidermis (Figure 6). Individual non-viable (dead) cells could 
only be quantified immediately after application (t = 0 h) by confocal microscopy. Even 
though Draize scores were low (typically 0-1) for eMPA and not present for i.d. at t = 24 h, 
images taken at t = 24 h and t = 72 h confirmed the presence of non-viable cells (Figure 6A 
and B). At t = 24 h, the cell death appears to have spread further than at t = 0 h which may be 
due to either easier accessibility of the ethidium bromide dye staining disintegrating cells at 
each site or additional cell death such as necroptosis [55]. At t = 0 h the dMPA had visually 
induced the highest proportion of dead cells that seemed to lyse similar to the eMPA at t = 24 
h (Figure 6C). This was reflected in Figure 6D, where quantification of dead cells at t = 0 h 
resulted in a clear trend of increasing number of dead cells from i.d. < eMPA < dMPA. 
Plotting the total number of dead cells against the epidermal mm2 × mJ indicated that mm2 × 
mJ on a log10 scale correlated with the number of dead cells. Overall, the eMPA resulted in 
significantly more total cell death (9614 ± 1359, p=0.0005) within the epidermis than the i.d. 
injection (1227 ± 904), while the dMPA (18297 ± 1271) resulted in the most epidermal cell 
death (i.d. p < 0.0001, eMPA p = 0.0013, Figure 6D). Although it is important to note that not 
all non-viable cells would have been accounted for during the larger volumes displaced in the 
epidermis by the i.d. and dMPA – as apparent by the black spaces in the images (Figure 6, t = 
0 h). This analysis further supports that the eMPA application to skin results in a relatively 
low local skin inflammation. Additionally, the cell death imaging specifically highlights the 
prolonged effect microprojection skin penetration has on the epidermal cells (i.e. cell death 
still visible up to 72 h, despite Draize scores of zero). 
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Figure 6: Application of eMPA induces less epidermal cell death than dMPA. 
Quantification and representative 3D reconstructed image of flank skin (~50 µm deep), 20x 
magnification, images of skin stained  for viable/live (green) and non-viable/dead (pink) cells 
taken at time points 0 h, 24 h and 72 h after application of (A) 20 µl i.d. 31G, (B) eMPA and 
(C) dMPA, scale bar: 200 µm.  (D) Quantification of dead cells in the epidermis at t = 0 h, n 
= 3 mice, mean ± SD. 
 
eMPA application induces LC migration but not dDC migration 
To assess whether the eMPA targeted specific resident APCs in the flank skin, we excised 
inguinal dLNs at t = 24, 48 and 72 h after eMPA or dMPA application (with PBS-based or 
OVA-based coating). During this time-frame (in naïve mice), DCs are only expected to 
migrate out of the skin in response to the MPA application based on previous reports on DCs 
in skin after MPA application [56-58]. Therefore, DC re-population of the skin after 
application was not assessed. Multi-colour flow cytometry was used to identify distinct DC 
subsets, including ‘total DC’ which subsets to resident DC, ‘Res DC’ or migratory DC ‘Mig 
DC’. Mig DC further subsets to migratory LC ‘Mig LC’ or migratory dDC ‘Mig dDC’ (see 
Figure 7A for the gating strategy). These populations were defined by: total DCs (CD11c+ 
MHC II(lo/hi)) cells that were subdivided using mean florescent intensity (MFI) histograms 
into Res DC (CD11c+ MHC II (lo)) and Mig DC (CD11c+ MHC II (hi)). Mig DCs were then 
further sub-populated to Mig LCs (CD11c+ MHC II (hi) CD11b+ EpCAM+) and Mig dDCs 
(CD11c+ MHC II (hi) CD11b+ EpCAM(lo)). 
 
Compared to dLNs from naïve mice, there were no significant differences between the 
numbers of live, single cells in any condition (SUPP 7). Concurrently, within each 
application group, there was no difference between total number of cells between time points 
t = 24, 48 or 72 h, nor between delivery of PBS or OVA within the Mig LC population nor 
within the Mig dDC population (SUPP 7). We henceforth compared eMPA and dMPA by 
combining data from all three time points and both formulations (PBS and OVA, n = 18). 
The total number of DCs between naïve, eMPA and dMPA was similar (p = 0.57) (SUPP 8), 
while the dMPA-treated dLNs demonstrated the presence of more Mig DCs, although not 
significantly (p = 0.053) (SUPP 8). Expression levels (MFI) of MHC II were significantly 
higher on the dMPA Mig DCs (naïve p = 0.0008, eMPA p < 0.0001) than the eMPA Mig 
DCs (p = 0.0003) (Figure 7B, right). Conversely, the eMPA dLNs contained more Res DCs 
than both the naïve (p < 0.0001) and dMPA (p < 0.0001) (SUPP 8). Both eMPA Res DCs 
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(Figure 7B, left) and Mig DCs (Figure 7B, right) expressed lower levels of MHC II than 
respective dMPA populations (p < 0.0001). Overall, the eMPA and dMPA induced LC 
migration while only the dMPA resulted in dDC migration (Figure 7C and D). Compared to 
naïve, the eMPA increased Mig LCs (number p < 0.0001, percent p = 0.0003) slightly more 
than the dMPA (number p = 0.0004, percent p = 0.0016), although this was not significant 
between the two MPAs (p = 0.83). While, the dMPA induced significantly more Mig dDCs 
than the eMPA (number p = 0.0014, percent p < 0.0001). Therefore, the eMPA preferentially 
targeted LCs while the dMPA targeted both LCs and dDCs. 
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Figure 7: eMPAs result in specific migration of epidermal LCs. Quantification of 
migratory LCs and dDCs in inguinal dLN from combined time points and antigen conditions 
of either eMPA (▼) or dMPA (●) applications compared to naïve (-) mice. (A) Gating 
strategy to identify and quantify cell populations. (B) Graphs of the Mean Fluorescence 
Intensity (MFI) of MHC II for Res DC (left) and Mig DC (right). (C) Total number of Mig 
LC (left) and Mig dDC (right) cell populations. (D) Percent of Mig LC (left) and Mig dDC 
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(right) cell populations from DC population. MPA groups included n = 9 mice with n = 18 
dLNs per group; naïve group n = 4 mice (n = 8 dLN). Graph: mean ± SD. 
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Discussion  
This is first reported study (to our knowledge) of the rapid delivery of biomolecules targeted 
to viable epidermis of mice, whilst maintaining a low local inflammatory response.  In 
achieving this, our findings open up exploration of the capabilities of the mouse model for 
therapies that would benefit from low inflammatory LC targeting such as asthma, AIT and 
chronic obstructive pulmonary disease. The study used polycarbonate MPAs, which is an 
inexpensive material that is well tolerated well by the skin’s immunity [59]. Thus, a 
polycarbonate eMPA is a suitable candidate for repetitive, immune downregulating therapies 
such as AIT. We have shown that blunt-tipped eMPA designs deliver OVA antigen primarily 
to the epidermis of mouse flank skin, and preferentially induce LC migration. This is 
achieved with lower levels of skin inflammation than is induced by a dMPA. Additionally, 
Cohn et al. [24] showed that patient compliance significantly increases if AIT treatment 
duration is less than 15 minutes [24-26]. As is consistent with MPA application times 
previously reported in the literature [60, 61], the eMPA delivered the desired dose (0.1 µg) of 
OVA within two minutes. Although coating methods used in this report were crude, leading 
to a low delivery efficiency (SUPP 1), using a more efficient coating method such as dip 
coating or inkjet coating would improve dose sparing effects of eMPA delivery to 
Langerhans cells [62, 63].  
 
Conical-MPA and slit-MPA projections were designed and tested at a variety of set 
application energies. In agreement with previous work of the microneedle field [42, 44, 64, 
65] , conical-MPAs were unable to deliver to the shallow mouse epidermis alone. For 
example, when Crichton et al. [44], used a similar application energy (26 mJ), the conical-
MPA penetrated into the dermis of ear skin. Conversely, the slit-MPAs were initially reported 
to increase penetration depth into mouse skin [40]. Yet, using polycarbonate slit-MPAs with 
a larger (blunter) tip surface area (Figure 1F), led to reduced penetration into the skin that 
could be maintained at a lower application energy (Figure 3), thus generating less cell death 
(Figure 6) and ultimately less skin inflammation (Figure 4 and Figure 5). This study is the 
first to show MPAs can be re-designed to not only target the epidermis but also maintain low 
skin inflammation despite a relatively high-density (7,000 projection/cm2). This approach 
builds upon insights into the viscoelasticity of the skin and the mechanical application of 
MPAs thereof [44, 66, 67].  
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The closest epidermal-targeted MPA design to the eMPA previously reported is by Crichton 
et al. [44], which delivered OVA to the epidermal-dermal junction of mouse skin when 
applied by hand. Crichton et al. investigated the same MPA applied using a spring applicator 
at a range of application energies that led to penetration from the epidermal-dermal junction 
into approximately one third into mouse dermis. Interestingly, when application energy 
decreased, anti-OVA IgG response decreased (now known to be Th2-biased from 
unpublished data). Suggesting that lower application energies are necessary to avoid immune-
activating responses. Additionally, Depelsenaire et al. reported that by halving the number of 
dMPA projections per MPA (from 3360 to 1600) induced a significantly lower titre of anti-
Fluvax IgG after delivery of influenza vaccine [33]. This indicates that MPA surface area 
applied to the skin can correlate with the level of immune activation. This avenue of changing 
the MPA design and application conditions to alter specific immunity is yet to be explored 
systematically. Together, these studies suggest that the combination of decreased application 
energy and delivery surface area (i.e. mm2 × mJ) would also lead to a reduced immune-
activating response. The eMPA has a significantly lower mm2 × mJ than the dMPA, 
supporting its suitability to avoid the induction of immune-activating responses.  
 
The LCs of the skin are well known to elicit either an antigen-specific immune regulation 
(e.g. Treg) [68, 69] or immune activation (e.g. Th1/Th2) [22, 70], however, the inflammatory 
threshold for LC-induced immune activation is yet to be determined. The eMPA defined here 
induces less skin inflammation than the dMPA, primarily penetrating into the epidermis, 
resulting in strata-specific APC migration (Figure 7). In comparison to more inflammatory 
(erythema present > 24 h) mouse epidermal-based delivery devices tested for AIT, such as 
ablative micro-fractional laser, OVA only administration increased allergic responses (Th2) 
and so additional Th1 adjuvants were required to prevent Th2 activation  [71, 72]. While, 
delivery methods with low associated inflammatory responses, such as Viaskin®, enhanced 
Treg responses and prevented specific-Th2 activation in challenged mice [73, 74]. Although 
Viaskin® has shown great promise in AIT [31] by targeting delivery to the epidermis [15], 
each application repeat still takes 48 hours [75].  Even though T cell responses are still to be 
investigated for the eMPA, we hypothesis that the eMPA would preferentially activate 
tolerance similar to Viaskin®. 
 
While delivery into the epidermis was achieved, it was also important in this study to assess 
that potential therapies would be taken up by the resident LCs and presented in the skin 
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dLNs. Here, we have shown that the eMPA specifically activated only LC migration while 
dMPA activated both LC and dDC migration (Figure 7). Interestingly, despite only inducing 
half the number of dead cells in the epidermis (Figure 6D), the eMPA dLNs contained the 
same number of migrating LCs (Mig LCs) as the dMPA. This is supported by Fernando et al. 
[76] who predicted that a dMPA of 16 mm2 (as used here) would target therapeutic to 
approximately 2000 out of the 10,000 LCs available to migrate in mouse skin. It is possible 
that here, we have highlighted that there is a localised threshold of number of dead cells 
required to activate LC migration. So, even though the eMPA killed the lowest number of 
cells (relative to the dMPA and Fernando’s dMPA), the number of dead cells killed by the 
eMPA is likely to still be above the minimal threshold to activate the same ratio of LCs as 
higher levels of cell death. This, however, does not address the maturation state of the 
migrated LC. Nakano (2012) [77] reported higher MHC II expression on DCs is required for 
Th2 priming in mice (and rats [78]) and correlates with an increase in Th1 activation. 
Therefore, because the expression of MHC II on Mig DC after eMPA was significantly lower 
than the Mig DCs of the dMPA (Figure 7B), the dMPA Mig DCs are significantly more 
likely to prime for effector T cell responses than the eMPA. Based on previous reports of 
MPAs similar to the dMPA, Ng et al. [79] found high-density dMPAs preferentially activated 
CD8+ T cells, while Shakya et al. [80] found low-density dMPAs induced a Th1-skewed 
response. Additionally, the eMPA dLNs contained a higher ratio of Res DCs than the dMPA 
similar to ratios seen in Viaskin® application, a device that has several promising results in 
AIT [15]. We hypothesise that, as the eMPA does not activate dDC migration nor high levels 
of skin inflammation, it is less likely to activate immunity like the dMPAs and is more likely 
to deliver antigen to the LCs for specific tolerance. To test this, eMPAs should be 
investigated in future mouse model experiments of low inflammatory LC targeted 
immunotherapies such as asthma, AIT and chronic obstructive pulmonary disease. 
 
Conclusion 
Here, we describe an MPA specifically targeting the epidermal layer of skin in mice – the 
eMPA. The eMPA caused a lower level of skin inflammation response relative to a dMPA. 
To achieve this, the eMPA was designed to have a high-density of blunt tipped projections 
which was applied with a low energy. Additionally, the eMPA device can specifically target 
the LCs of the skin without activating dDC. Due to the specific cell targeting, eMPAs could 
lead to higher therapy efficiency using lower doses (i.e. making them safer and cheaper), 
increasing availability of the treatment and patient compliance. Therefore, this device 
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provides a valuable tool for the necessary studies to advance LC targeting with a practical 
device from pre-clinical tests in mice to epidermal-based therapies in patients. 
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HIGHLIGHTS 
 First microprojection array to deliver primarily to the epidermis of mouse skin. 
 The eMPA rapidly delivered ovalbumin with a low skin inflammation response. 
 The eMPA preferentially promotes Langerhans cell migration out of skin. 
ACCEPTED MANUSCRIPT
